Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.

ID
Name
[616856-4]
Description
In this investigator-initiated study, we will compare changes in brain cognitive biomarkers assessed by diffusion tensor imaging over 2.5 years among 12 patients with Idiopathic Parkinson's disease (IPD) receiving rasagiline, 20 IPD patients not receiving MAO-B inhibitors and 25 age-matched healthy controls. Will also compare the changes in Mini-Mental State Exam (MMSE) and Montreal Cognitive Assessment (MoCA) scores and plasma brain-derived neurotrophic factor (BDNF) with changes in brain cognitive biomarkers in all IPD patients and HC over 2.5 years.
Trial arms
Trial start
2014-11-01
Estimated PCD
2017-12-01
Trial end
2017-12-01
Status
Completed
Treatment
Rasagiline
Arms:
PD-R
Other names:
Azilect
Size
45
Primary endpoint
Change in cognitive biomarkers assessed by DTI
2.5 years
Comparison of change in cognitive biomarkers with change in MMSE and MoCA scores
2.5 years
Eligibility criteria
IPD or HC subjects who were enrolled in a similar study about 2.5 years ago and for whom Baseline DTI data are available.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 45, 'type': 'ACTUAL'}}
Updated at
2023-02-14

1 organization

1 product

1 indication

Organization
State University of New York at Buffalo
Product
Rasagiline
Indication
Parkinson's Disease